Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTION-RCC phase 2 study of nivolumab-based combination therapies in advanced renal cell carcinoma
2016-003082-26Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, relatlimab and linrodostat in renal cell carcinoma (RCC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-003082-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003082-26.